AAV Production in Culture Biosciences’ 250mL Bioreactors
Adeno-associated virus (AAV) is a critical vector in gene therapy, but process robustness and scalability can pose challenges. This whitepaper demonstrates how Culture Biosciences' on-demand fleets of 250mL bioreactors enable large-scale experimentation and real-time data access to optimize upstream processes. Learn how process optimization can increase the fraction of full AAV capsids, accelerating your path to market.
GMP Validated Next Generation Sequencing Services: Viral Safety Testing & Genetic Characterization
March 26th 2025This brochure will expand on our NGS testing services to biopharmaceutical and biotech companies, including viral contamination testing and genetic characterization of cell lines, bulk harvests, virus seeds, and raw materials used for production of biologics including cell and gene therapy products.
Develop Potency Assays Early for ATMP Success
March 26th 2025Early potency assay development and MOA understanding are critical for ATMP success. Delays can increase costs and risk failure, but recent advances highlight the need for timely, validated approaches to ensure regulatory and commercial success.
Engage with Industry Leaders on Viral Clearance & Viral Safety at 2025 Summit
March 26th 2025Join on June 3-4 in Cologne, Germany to gain insights from leading regulatory authorities, academics, and industry practitioners who define how biologics, vaccines, and advanced therapeutic medicinal products (ATMPs) are evaluated. Discover the latest technologies, learn best practices, and understand how to design an efficient manufacturing process.
